Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla

Henrietta Strickland
September 15, 2020

"I know the world wants to be optimistic on it.[but] I have not heard of anyone coming even close to that [level] right now", he told Financial Times in an interview, fanning concerns that countries like the USA would push poorer countries to the rear-end of the queue. He had earlier predicted that if the coronavirus shot is a two-dose vaccine, as is the case with measles or rotavirus, then the world would require 15 billion doses.

Adar Poonawalla, CEO of the Serum Institute of India, has warned that it will take at least four years to make enough Covid-19 vaccines for the entire world, according to an interview in the Financial Times.

In an interview with the Financial Times, Adar Poonawalla, chief executive of the Serum Institute of India, said that pharma firms were not ramping up production capacity swiftly to be able to innoculate the world population in less duration.

The company may also partner with Russia's Gamaleya Research Institute to manufacture the Sputnik vaccine. But, I haven't heard of anyone approaching even close to this level now, he told the FT.

He assured the vaccine will be first made available to those who need it the most, irrespective of their paying capacity.

He further stated: Issues such as vaccine safety, security, cost, cold chain requirements, equity, and production schedules, etc. have also been considered profoundly. "This shall be done after a consensus has been reached", he said, according to an official statement.

The company is also responsible for making COVID-19 vaccine doses for a large chunk of the developing world, according to the Financial Times. According to the agreement with Novavax, the vaccine targets 92 countries/regions.

Last week, the Oxford vaccine candidate from Astra Zeneca halted human trials when a volunteer fell ill in the United Kingdom, after which the Serum Institute of India also stopped trials - citing a show-cause notice issued form the Drug Controller of India.

After the developments, India's top pharmaceutical regulator has asked SII to suspend any new recruitment for the second and third phases of clinical trials of the COVID-9 vaccine until further orders are obtained.

SII presently produces 1.5 billion doses of polio, measles and influenza vaccines for 170 countries.

Meanwhile, the global death toll from the coronavirus has risen to 929,000 with 29 million infections on Monday.

Due to the fallout of the pandemic, a worldwide race for a vaccine is underway, with nine companies already in late-stage Phase 3 trials.

When will the COVID-19 vaccine be ready?

Other reports by Click Lancashire

Discuss This Article